The North America dyslipidemia drugs market is expanding steadily, supported by the rising burden of cardiovascular disorders, increasing focus on preventive healthcare, and growing adoption of advanced lipid-lowering medications. Favorable healthcare infrastructure, ongoing clinical research, and the presence of major pharmaceutical companies are contributing to market growth. Increasing...